Bio News
Apnimed is pursuing an IPO of up to $160 million (approximately 240 billion won) to commercialize the sleep apnea drug AD109. In a phase 3 trial, AD109 reduced the number of nighttime breathing pauses by 46.8%, and U.S. Food and Drug Administration (FDA) approval is expected in February next year. The company plans to sell 10 million shares at $14-$16 per share to prepare for commercialization.
BIOBOOK TEAM
biobookmedia@biobook.co.krMinistry of Trade, Industry and Energy and Ministry of Food and Drug Safety Sign Agreement on AI Transformation and Global Competitiveness in Biotech
Paragon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Roche Signs $1.6 Billion Deal With China’s Rona for ALK7 Obesity Drug
Formycon and Zydus’ Keytruda Biosimilar Is First to Be Accepted for FDA Review
